Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Debt / NOTE 2.250% 3/0
-
Market price (% of par)
-
106.45%
-
Total 13F principal
-
$257,273,349
-
Principal change
-
+$257,273,349
-
Total reported market value
-
$279,703,965
-
Number of holders
-
23
-
Value change
-
+$279,703,965
-
Number of buys
-
23
Institutional Holders of TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 as of Q1 2022
As of 31 Mar 2022,
TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 was held by
23 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$257,273,349
in principal (par value) of the bond.
The largest 10 bondholders included
WOLVERINE ASSET MANAGEMENT LLC, D. E. Shaw & Co., Inc., LAZARD ASSET MANAGEMENT LLC, DeepCurrents Investment Group LLC, CITADEL ADVISORS LLC, Linden Advisors LP, CAPSTONE INVESTMENT ADVISORS, LLC, HIGHBRIDGE CAPITAL MANAGEMENT LLC, AVIVA PLC, and Polar Asset Management Partners Inc..
This page lists
23
institutional bondholders reporting positions
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.